Equities

Jiang Zhong Pharmaceutical Co Ltd

600750:SHH

Jiang Zhong Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.40
  • Today's Change-1.81 / -8.96%
  • Shares traded7.78m
  • 1 Year change-14.02%
  • Beta0.7549
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jiang Zhong Pharmaceutical Co Ltd is a China-based company mainly engaged in the pharmaceutical manufacturing industry. The Company's products are classified into over-the-counter drugs, prescription drugs, big health products and others, covering the fields of spleen and stomach, intestines, throat, tonic, rehabilitation nutrition, high-end tonic, cardiovascular and cerebrovascular, gynecology, urinary system and others OTC products include Jianweixiaoshi Tablets, Lactobacillus Tablets, Compound Coral Grass Tablets, and Bifidobacterium Triple Live Enteric Capsules. Health products mainly include peptides and protein powder products. Prescription drug products include Chinese medicine products such as Bazhen Yimu Capsules, Shenbao Capsules, Paishi Granules, Huangqi Shengmai Yin, Zhenju Jiangya Tablets, Shuangju Granules, Zhikang Tablets, Shuxiong Granules and others

  • Revenue in CNY (TTM)4.22bn
  • Net income in CNY753.16m
  • Incorporated1996
  • Employees4.01k
  • Location
    Jiang Zhong Pharmaceutical Co LtdNo. 788, Huoju Avenue, High-Tech ZoneNANCHANG 330096ChinaCHN
  • Phone+86 79 188169323
  • Fax+86 79 188162532
  • Websitehttps://www.jzjt.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
600750:SHH since
announced
Transaction
value
Jiangxi Jiangzhong Traditional Chinese Medicine Decoction Pieces Co LtdAnnounced26 Oct 202426 Oct 2024Announced-18.37%12.10m
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tibet Rhodiola Pharmaceutical Holding Co2.94bn737.44m11.73bn601.0014.113.23--3.992.582.589.6911.260.62641.546.794,894,779.0015.8012.4420.8315.7193.3690.5125.2220.433.447.740.126450.4122.6924.98116.5630.01-1.4848.97
Jiangxi Tianxin Pharmaceutical Co Ltd2.01bn557.43m11.78bn2.47k21.152.64--5.871.271.274.5810.180.39772.7510.26812,720.6011.04--11.82--41.64--27.76--6.39--0.0234---18.34---23.51------
Henan Lingrui Pharmaceutical Co., Ltd.3.56bn675.80m11.81bn2.53k17.344.08--3.311.201.206.345.100.74892.2410.181,408,620.0014.2010.6823.5216.5672.3574.4218.9614.920.9579--0.007372.8010.3110.0322.0918.49-16.4739.77
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.58bn421.47m11.82bn1.55k28.554.52--7.501.881.887.1411.910.42861.193.671,020,281.0011.585.8616.997.5967.1255.4127.0117.200.91224.020.347727.5958.6932.2426.2029.9927.32--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.46bn486.79m11.85bn8.41k24.111.78--1.830.19120.19122.542.590.6182.394.56768,224.604.986.776.9310.5051.4763.248.0611.101.24--0.078142.3212.20-0.826765.20-6.21-11.645.92
Guobang Pharma Ltd5.71bn702.28m12.04bn4.23k17.091.54--2.111.261.2610.2614.030.55993.297.841,350,536.006.8710.368.8814.2423.8727.4912.2715.011.70--0.199218.24-6.4910.28-33.4923.7735.60--
Jiang Zhong Pharmaceutical Co Ltd4.22bn753.16m12.71bn4.01k16.853.42--3.011.201.206.715.910.68283.5815.121,052,061.0013.3610.8220.7215.0863.7265.0219.5618.170.8833--0.000482.8813.0020.1218.408.5411.4740.99
Zhejiang Jiuzhou Pharmaceutical Co Ltd4.91bn697.36m13.17bn4.88k18.981.55--2.680.77490.77495.459.510.44051.754.201,007,191.006.2810.107.6713.6932.6134.6414.2516.262.48--0.090940.791.4424.2912.2045.7432.1420.11
BrightGene Bio-Medical Technology Co Ltd1.24bn188.08m13.37bn1.16k70.875.68--10.770.44660.44662.965.570.25221.633.501,074,862.002.916.533.577.9354.9756.9311.5519.901.184.530.484129.3115.9423.68-15.5122.5629.13--
Data as of Sep 13 2024. Currency figures normalised to Jiang Zhong Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

15.19%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 30 Sep 202334.50m5.53%
China Investment Corp. (Investment Management)as of 30 Sep 202315.55m2.49%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 202414.64m2.35%
Ping An Fund Management Co., Ltd.as of 30 Sep 20237.83m1.26%
First Seafront Fund Management Co., Ltd.as of 30 Jun 20247.18m1.15%
HuaAn Fund Management Co., Ltd.as of 30 Jun 20245.31m0.85%
China Universal Asset Management Co., Ltd.as of 30 Jun 20243.62m0.58%
China Southern Asset Management Co., Ltd.as of 30 Jun 20242.18m0.35%
Baoying Fund Management Co., Ltd.as of 30 Jun 20242.06m0.33%
Orient Securities Asset Management Co. Ltd.as of 30 Jun 20241.84m0.30%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.